Cerevel Therapeutics (CERE) PT Raised to $29 at Mizuho Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts CERE Hot Sheet
Price: $44.96 --0%
Rating Summary:
5 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
5 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Mizuho Securities analyst Graig Suvannavejh raised the price target on Cerevel Therapeutics (NASDAQ: CERE) to $29.00 (from $26.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Citi Downgrades Bank Rakyat Indonesia Persero Tbk PT (BBRI:IJ) (BKRKF) to Neutral
- Ventive Hospitality (VENTIVE:IN) PT Lowered to INR638 at Axis Capital Limited
- Damai Entertainment Holdings (1060:HK) PT Lowered to HK$0.64 at Citi
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
